c-LEcta, a German biotech company located in Leipzig, has developed an advanced nuclease product, DENARASE®, designed for nucleic acid removal in biopharmaceutical production processes. Unlike other nuclease types, which usually are produced using Escherichia coli as expression host, c-LEcta’s DENARASE is manufactured using a patent protected production process based on a Bacillus strain and a fermentation medium free of any antibiotics and animal derived products.  Beside the absence of endotoxins in gram-positive bacteria like Bacillus and the absence of antibiotics…